Meet the Expert Symposium

Fights Neuroendocrine Tumors!

6/19 THU **19:00 - 20:40**

大倉久和飯店 3F 秋宜-冬余廳

Jennifer Chan

Dana-Farber Cancer Institute, USA

Jennifer Chan, MD, MPH, is an associate professor of medicine at Harvard Medical School and an institute physician in the Division of Medical Oncology at Dana-Farber Cancer Institute, both in Boston, MA. She also serves as director of the Neuroendocrine and Carcinoid Tumors Program and clinical director of the Gastrointestinal Cancer Center at the Dana-Farber Brigham Cancer Center.

She focuses her clinical practice on the care of patients with neuroendocrine tumors (NETs) and gastrointestinal cancers. She has been principal investigator of multiple clinical trials investigating novel therapies for NETs, and she has been involved in studies examining factors that are associated with clinical outcomes in patients with NETs. She is the first author of the CABINET study publication in The New England Journal of Medicine (NEJM).

TIME	TOPIC	SPEAKER	MODERATOR
19:00-19:05	**Opening**	**陳明晃 醫師** 台北榮總 腫瘤醫學部	
19:05-19:45	**Advancing Neuroendocrine Tumor Treatment: Insights from the CABINET study and the future prospect of cabozantinib**	**Jennifer Chan** Dana-Farber Cancer Institute, USA	**陳明晃 醫師** 台北榮總 腫瘤醫學部
19:45-20:20	**Advancing Neuroendocrine Tumor Treatment: Insights from combination regimen and future prospect of lanreotide**	**蔡慧珍 醫師** 成大醫院 腫瘤醫學部	**王秀伯 醫師** 台大醫院 胃腸肝膽科
20:20-20:35	**Panel Discussion**		**ALL**
20:35-20:40	**Closing**	**王秀伯 醫師** 台大醫院 胃腸肝膽科	

僅限醫療人員參加

學會教育積分(申請中)：台灣外科醫學會、台灣內科醫學會、台灣消化系外科醫學會、台灣消化系醫學會、台灣內視鏡外科醫學會、台灣消化系內視鏡醫學會、中華民國癌症醫學會

現場會議報名

線上會議註冊

共同主辦: TNETS 台灣神經內分泌腫瘤學會 Taiwan NeuroEndocrine Tumor Society

IPSEN Innovation for patient care

CBZ-TW-000047

Jennifer Chan, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Institute Physician, Division of Medical Oncology
Dana-Farber Cancer Institute
Boston, MA

Jennifer Chan, MD, MPH, is an associate professor of medicine at Harvard Medical School and an institute physician in the Division of Medical Oncology at Dana-Farber Cancer Institute, both in Boston, MA. She also serves as director of the Neuroendocrine and Carcinoid Tumors Program and clinical director of the Gastrointestinal Cancer Center at the Dana-Farber Brigham Cancer Center.

Dr Chan is a graduate of the University of Virginia. She received her medical degree from Harvard Medical School and her masters of public health degree from the Harvard T.H. Chan School of Public Health. She completed her internal medicine residency at Brigham and Women's Hospital, followed by a fellowship in medical oncology at Dana-Farber Cancer Institute.

She focuses her clinical practice on the care of patients with neuroendocrine tumors (NETs) and gastrointestinal cancers. She has been principal investigator of multiple clinical trials investigating novel therapies for NETs, and she has been involved in studies examining factors that are associated with clinical outcomes in patients with NETs.

Dr Chan is a past chair of the North American Neuroendocrine Tumor Society (NANETS) Guidelines Committee and serves on the National Comprehensive Cancer Network Neuroendocrine Tumors Guidelines Panel. She co-chairs the Alliance for Clinical Trials in Oncology Neuroendocrine Tumor Working

Group. In addition, she is a member of the National Cancer Institute Neuroendocrine Tumor Taskforce and the NANETS Board of Directors.

Publications & Presentations

PubMed

218 citations

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

Andrew X. Zhu, Jeffrey A. Meyerhardt, Lawrence S. Blaszkowsky, Avinash Kambadakone, Alona Muzikansky

The Lancet. Oncology. 2010-01-01

202 citations

Cytogenetic Prognostication Within Medulloblastoma Subgroups

David Shih, Paul A. Northcott, Marc Remke, Andrey Korshunov, Vijay Ramaswamy

Journal of Clinical Oncology. 2014-03-20

123 citations

Antibodies from Inflamed Central Nervous System Tissue Recognize Myelin Oligodendrocyte Glycoprotein

Kevin C. O'Connor, Heiner Appel, Lisa Bregoli, Matthew E. Call, Ingrid Catz

Journal of Immunology. 2005-08-01

Other

Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth

Chan JA, Kulke M

http://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-optio

UpToDate, Wolters Kluwer Health - 2013-04-15

Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring

Chan JA, Kulke M

http://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-presentatio

UpToDate, Wolters Kluwer Health - 2012-07-05

Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion

Chan JA, Kulke M

http://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-systemic-th

UpToDate, Wolters Kluwer Health - 2013-02-05

Press Mentions

Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or Pancreatic Neuroendocrine

TumoursCabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or Pancreatic Neuroendocrine Tumours

October 25th, 2024

Cabozantinib Improves PFS for Advanced Neuroendocrine TumorsCabozantinib Improves PFS for Advanced Neuroendocrine Tumors

September 17th, 2024

Team Publishes Results from Clinical Trial Evaluating Cabozantinib in Advanced Neuroendocrine TumorsTeam Publishes Results from Clinical Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors

September 16th, 2024

CURRICULUM VIATE

Name: Hui-Jen Tsai, M.D. PhD.

Institute: National Institute of Cancer Research, National Health Research Institutes

Department of Oncology, National Cheng Kung University Hospital

Address: No.367, Sheng Li Road, Tainan 70456, Taiwan R.O.C.

Tel: (O) 886-6-7000123 ext.65149

Fax : (O) 886-6-2083427

E-mail: hjtsai@nhri.org.tw

EDUCATION:

1989.9 - 1993.6 Bachelor. National Chiao Tung University, Hsinchu, Taiwan

1993.9 - 1998.6 M.D. Kaohsiung Medical University, Kaohsiung, Taiwan

2005.9 – 2014.7 PhD. Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

POSTDOCTORAL TRAINING and EXPERIENCE

2023.12- Deputy director, National Institute of Cancer Research, National Health Research Institutes

2020.10 - Associate Investigator, National Institute of Cancer Research, National Health Research Institutes

2019.9- 2019.10 Visiting observership, Department of Experimental Therapeutics and Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tsukiji, Japan

2015.10- 2020.9 Assistant Investigator, National Institute of Cancer Research, National Health Research Institutes

2011.1 - 2015-9 Attenting Physician, National Institute of Cancer Research, National Health Research Institutes

2008.2 - 2010.7 Attending Physician, Division of Hematology/Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital.

2006.8 - 2008.1 Visiting Researcher, Division of Molecular Therapy, The Institute of Medical Science, The University of Tokyo

2003.8-2006.7 Attending Physician, Division of Hematology/Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital.

2001.8 - 2003.7 Chief Resident, Division of Hematology/Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital

1998.8 - 2001.7 Residency training, Department of Internal Medicine, Kaohsiung Medical University Hospital

1997.6 - 1998.5 Internship, Kaohsiung Medical University Hospital

LICENSURE AND CERTIFICATION:

1998 National Medical Board of Republic of China

2001 Specialist of Internal Medicine, Taiwan, R.O.C.

2003 Specialist of Hematology, Taiwan, R.O.C.

2004 Specialist of Medical Oncology, Taiwan, R.O.C.

HOSPITAL APPOINTMENTS:

2020.10 – Attending Physician, Department of Oncology, National Cheng Kung University Hospital

2011.1 – 2020.9 Attending Physician, Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital

2003.8 – 2010.7 Attending Physician, Division of Hematology/Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital

MEMBERSHIPS:

2001 Taiwan Society of Internal Medicine.

2003 The Hematology Society of Taiwan.

2004 The Chinese Oncology Society.(R.O.C)

2008 The American Society of Hematology

Selected Publications:

1. Chang TM, Fang WY, Hsu HP, Chu PY, Jiang SS, Huang KW, Hung WC, Lin HY, **Tsai HJ****. PCK2 promotes invasion and epithelial-to-,esenchymal transition in triple-negative breast cancer by promoting TGF-β/SMAD3 signaling through inhibiting TRIM67-mediated SMAD3 ubiquitination. ***Cancer Biology & Therapy*** 2025;26(1):2478670. (IF (2023):4.4，5-year impact factor:4.4, Journal ranking: Oncology: 86/322 (Q2)) (Corresponding author).
2. **Tsai HJ***, Yeh KH, Lin CW, Wu MS, Liou JM, Hsu PN, Zeng YH, Wei MF, Shun CT, Wang HP, Chen LT, Cheng AL, Kuo SH. Cooperative participation of CagA and NFATc1 in the pathogenesis of antibiotics-responsive gastric MALT lymphoma. ***Cancer Cell International*** 2024 Nov 18;24(1):383. (IF (2023):5.3，5-year impact factor:5.0, Journal ranking: Oncology : 62/322 (Q1)) (first author).

2. Tsai HJ*, Yang SH, Hsiao CF, Kao HF, Su YY, Shan YS, Yen CJ, Du JS, Hsu C, Wu IC, Chen LT. A phase I study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study. ***Oncologist*** 2024 Oct 3;29(10):e1396-e1405. (IF (2023):4.8，5-year impact factor:5.3, Journal ranking: Oncology : 70/322 (Q1)) (first author)

3. Tsai HJ*, Shan YS, Yang CY, Hsiao CF, Tsai CH, Wang CC, Lin MT, Ting CF, Chan DC, Chen TH, Yen CC, Chen YY, Lin HY, Yeh TS, Ho CL, Shieh TY, Bai LY, Hsu JT, Chen IS, Chen LT, Yeh CN, Taiwan Cooperative Oncology Group (TCOG) GIST Study Group. Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: A nationwide registry study. ***BMC Cancer*** 2024 Jul 11;24(1):828. (IF (2023):3.4，5-year impact factor:3.8, Journal ranking:Oncology : 110/322 (Q2)) (first author)

4. Hsu HP, Chu PY, Chang TM, Huang KW, Hung WC, Jiang SS, Lin HY, **Tsai HJ.****

   Mitochondrial phosphoenolpyruvate carboxykinase promotes tumor growth in estrogen receptor-positive breast cancer via regulation of the mTOR pathway. ***Cancer Med.*** 2023 Jan;12(2):1588-1601. (IF (2023):2.9，5-year impact factor:3.9, Journal ranking:Oncology : 151/322 (Q2)) (corresponding author)

5. Chang TM[*], Chu PY[*], Lin HY, Huang KW, Hung WC, Shan YS, Chen LT, **Tsai HJ**.** PTEN regulates invasiveness in pancreatic neuroendocrine tumors through DUSP19-mediated VEGFR3 dephosphorylation. ***J Biomed Sci*** 2022;29:92. (IF (2022):11.0, 5-year impact factor:10.9, Journal ranking: Medicine, Research & Experimental: 13/136 (Q1))．(corresponding author**)**

6. Brose M, Smit J, Lin CC, Tori M, Bowles D, Worden F, Shen DH, Huang SM, **Tsai HJ**, Alevizaki M, Peeters RP, Takahashi S, Rumyantsev P, Guan R, Babajanyan S, Ozgurdal K, Sugitani I, Pitoia F, Lamartina L. Multi-kinase inhibitors for the treatment of asymptomatic radioactive iodine-refractory differentiated thyroid cancer. Global, non-interventional study (RIFTOS MKI). Thyroid 2022 Sep;32(9):1059-1068. doi: 10.1089/thy.2022.0061. (IF (2022):6.6, 5-year impact factor:6.6, Journal ranking: Endocrinology & Metabolism: 24/145 (Q1))．(co-author**)**

7. Tsai HJ*, Hsiao CF*, Chang JS, Chen LT, Chao YJ, Yen CJ, Shan YS. The prognostic and predictive role of chromogranin A in gastroenteropancreatic neuroendocrine tumors – A single-center experience. ***Front. Oncol.*** 2021(Nov);11:741096. (IF(2021):5.738，5-year impact factor:6.122, Journal ranking: Oncology: 78/245(Q2)) (First author)

8. Yang SR, Tsai MH, Hung CJ, Peng SL, Chiu NT, Huang YH, **Tsai HJ**.** Anaplastic thyroid cancer successfully treated with radiation and immunotherapy: a case report. ***AACE Clinical Case Rep*** 2021;7: 299-302. (corresponding author)

9. Chang JS, Chen LT, Shan YS, Chu PY, Tsai CR, **Tsai HJ****. An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan. ***Sci Rep*** 2021;11:7881. (IF(2021):4.997，5-year impact factor:5.516, Journal ranking: MULTIDISCIPLINARY SCIENCES: 19/74(Q1)) (corresponding author)

10. **Tsai HJ****, Shiah HS, Chang JY, Su WC, Chiang NJ, Chen LT. Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors. ***Sci Rep*** 2021;11:4834. (IF(2021):4.997，5-year impact factor:5.516, Journal ranking (JCI): MULTIDISCIPLINARY SCIENCES: 19/74(Q1)) (first and corresponding author)

11. Chang TM, Chu PY, Hung WC, Shan YS, Lin HY, Huang KW, Chang JS, Chen LT, **Tsai HJ**.** c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation. ***Cancer Sci*** 2021 Jan;112(1):243-253.

    (IF (2021):6.518，5-year impact factor:6.330 ,Journal ranking: Oncology : 62/245 (Q2))（corresponding author）

12. Lin CY, Chang JS, Huang SM, Hung CJ, Hung CL, Chang CT, Yang HR, Hsieh TC, Huang YH, **Tsai HJ**.** Experience of Sorafenib Treatment in Differentiated Thyroid Cancer from Taiwan. ***J Formosan Medical Association***. 2021;120:189-195. (IF (2021):3.871，5-year impact factor: 3.621, Journal ranking: Medicine, General & Internal: 61/172 (Q2))（**corresponding author)**

13. **Tsai HJ**, Tai JJ, Chen LT, Wu MS, Yeh KH, Lin CW, Wang TE, Wang HP, Yu FJ, Liou JM, Hsiao CF, Cheng TY, Yeh HJ, Ko CW, Chen MJ, Lo GH, Hsu PI, Chang CS, Hwang WS, Chuang SS, Lee HW, Shun CT, Chiu CF, Wang WM, Hsieh CY, Liu TW, Lin JT, Kuo SH, Cheng AL. A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue. ***Haematologica***. 2020 Jul;105(7):e349-e354 Epub 2019 Nov 14. (IF:9.941，Journal ranking: Hematology: 8/76 (Q1))(first author)

14. Lin WH,[#] Wu SY,[#] Yeh TK,[#] Chen CT, Song JS, Shiao HY, Kuo CC, Hsu T, Lu CT, Wang PC, Wu TS, Peng YH, Lin HY, Chen CP, Weng YL, Kung FC, Wu MH, Su YC, Huang KW, Chou LH, Hsueh CC, Yen KJ, Kuo PC, Huang CL, Chen LT, Shih C, **Tsai HJ**,* and Jiaang WT*. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors (GISTs) and Acute Myeloid Leukemia (AML). ***J Med Chem***. 2019 Dec 26;62(24):11135-11150. (IF:6.205，Journal ranking: Chemistry Medicinal: 3/61 (Q1))（co-corresponding）

15. Chen MH, Chou WC, Hsiao CF, Jiang SS, **Tsai HJ**, Liu YC, Hsu C, Shan YS, Hung YP, Hsieh CH, Chiu CH, Liu TC, Cho SF, Liu TW, Chai Y. An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic analysis for Poorly Differentiated Neuroendocrine Carcinomas. ***Oncologist.*** 2019 Dec 18. pii: theoncologist.2019-0490. doi: 10.1634/theoncologist.2019-0490. [Epub ahead of print] (IF:5.025，Journal ranking:Oncology : 65/244 (Q2)) (co-author)

16. Wu TS, Lin WH, **Tsai HJ**, Hsueh CC, Hsu T, Wang PC, Lin HY, Peng YH, Lu CT, Lee LC, Tu CH, Kung FC, Shiao HY, Yeh TK, Song JS, Chang JY, Su YC, Chen LT, Chen CT, Jiaang WT, Wu SY. Discovery of Conformational Control Inhibitors Switching off the Activated c-KIT and Targeting a Broad Range of Clinically Relevant c-KIT Mutants. ***J Med Chem***. 2019 Apr 25;62(8):3940-3957. (IF:6.205，Journal ranking: Chemistry Medicinal: 3/61 (Q1))（co-author）

17. Tsai HJ, Jiaang WT, Shih NY, Fletcher JA, Lin MJ, Yang MY, Chen CT, Hsu TA, Wu CC, Lin HY, Chen LT. BPR1J373, a novel multi-targeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor. ***Cancer Science*** 2018;109(11): 3591-3601. (IF:4.751，Journal ranking: Oncology : 57/229 (Q1))（ first and corresponding author）(highlight of the issue)

18. Chu PY*, Jiang SS*, Shan YS*, Hung WC, Chen MH, Lin HY, Chen YL, **Tsai HJ**, Chen LT. Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors. ***Oncotarget*** 2017;8(61):103613-103625.（corresponding author）

19. Chang TM*, Shan YS*, Chu PY*, Jiang SS, Hung WC, Chen YL, Tu HC, Lin HY, **Tsai HJ**, Chen LT. The regulatory role of aberrant Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors. ***Oncotarget*** 2017;8(58):98068-98083.（corresponding author）

20. Chen LT, Chen CT, Jiaang WT, Chen TY, Butterfield JH, Shih NY, Hsu JT, Lin HY, Lin SF, **Tsai HJ**. BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of *c-KIT* driven myeloid leukemia. ***Mol Cancer Ther*** 2016;15:2323-2333. (IF:5.764，Journal ranking: Oncology: 36/217(Q1))（corresponding author）

21. Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS. Second Cancers in Patients with Neuroendocrine Tumors. ***PLOS ONE*** 2013;Dec 31;8(12):e86414. (first author)

22. Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS. The Epidemiology of Neuroendocrine Tumors in Taiwan: a Nation-wide Registry-based Study. ***PLOS ONE*** 2013;Apr 22;8(4):e62487. (first author)